Multimodal deep learning model improves risk prediction for cervical cancer radiotherapy decisions

Published Date: 03 Sep 2025

Standard concurrent chemoradiotherapy (CCRT) for cervical cancer achieves disease-free survival (DFS) in approximately 70% of patients with locally advanced disease; however, nearly 30% still experience recurrence or metastasis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot